U.S. And Canada Skin Cancer Dermatology Market Is Set For Lucrative Growth To 2030

U.S. And Canada Skin Cancer Dermatology Market Summary

The U.S. and Canada skin cancer dermatology market size was valued at USD 2.07 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 5.5% from 2022 to 2030. This market expansion is primarily attributed to the increasing incidence of skin cancer across both countries.

Rising public awareness regarding early diagnosis, skin health, and available treatment options is further fueling market demand. Additionally, continuous technological advancements in dermatological equipment and diagnostic tools are playing a pivotal role in enhancing the accuracy and efficiency of skin cancer detection and management, thereby supporting market growth.

The COVID-19 pandemic, however, negatively impacted the dermatology industry in both the U.S. and Canada. During the peak of the outbreak, many dermatology clinics suspended operations, elective procedures were delayed, and the availability of medical supplies was disrupted.

According to a study published in the One Access journal PLOS ONE, the province of Ontario in Canada experienced a significant decline in total skin biopsies, reaching only 15% of the expected level at the onset of the pandemic. Notably, the study highlighted that females in the region were disproportionately less likely to receive biopsies during this period. Nevertheless, biopsy volumes increased considerably in the latter half of 2020, indicating a strong recovery in diagnostic activity.

Key Market Trends & Insights

• In the U.S., the American Academy of Dermatology reported that approximately 3.3 million individuals are diagnosed annually with basal and squamous cell skin cancers. It is further estimated that one in every five Americans will develop skin cancer at some point in their life. In Canada, nearly 7,800 new cases of melanoma and approximately 1,300 related deaths were documented in 2019, underlining the growing public health concern associated with skin malignancies in the region.
• Based on test types, the market is segmented into skin biopsy, dermatoscopy, diagnostic imaging, and lymph node biopsy. Among these, the skin biopsy segment accounted for the largest share, holding 32.3% of the market in 2021. This dominance is attributed to the widespread adoption of skin biopsy as a standard procedure for definitive diagnosis of various types of skin cancers, including melanoma and non-melanoma forms.
• In terms of facility types, the market is categorized into stand-alone practices, multispecialty clinics, dermatology groups, hospital outpatient departments (OPDs), and others. The hospital OPD segment led the market in 2021 with a substantial share of 40.2%. It is also anticipated to record the fastest growth rate between 2022 and 2030. This trend can be attributed to the increasing number of patients seeking specialized dermatological services in hospitals due to the availability of advanced diagnostic tools, highly trained personnel, and integrated care facilities.
• With respect to age groups, the market has been classified into several categories: 0–19 years, 20–39 years, 40–59 years, 60–64 years, 65–74 years, 75–84 years, and 85 years and above. The 40–59 years age group segment emerged as the largest contributor to market share in 2021, accounting for 26.3%. This age bracket includes a substantial proportion of the working population who are increasingly health-conscious and more likely to seek dermatological evaluations, especially for skin irregularities that could indicate early stages of cancer.

Order a free sample PDF of the U.S. And Canada Skin Cancer Dermatology Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2021 Market Size: USD 2.07 billion
• 2030 Projected Market Size: USD 3,395.97 million
• CAGR (2022 - 2030): 5.5%

Key Companies & Market Share Insights

Advancement in the field of skin cancer diagnosis and treatment is the key focus of competitors. The rising burden of skin cancer is expected to force major players to collaborate and discover advanced techniques for the efficient diagnosis of the disease. The key companies are concentrating on strategic initiatives, such as geographical expansions and strategic collaborations. For instance, in 2019, MetaOptima signed a national agreement with Sonic Healthcare to implement DermEngine software across Australian skin cancer centers.

Key Players

• Firefly
• SkinIO
• Canfield Scientific, Inc.
• FotoFinder Systems, Inc.
• 3Gen
• MetaOptima
• Agilent Technologies
• SkinVision
• Speclipse, Inc.
• Skin Analytics

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. and Canada skin cancer dermatology market is steadily expanding due to a rise in skin cancer prevalence, heightened public awareness, and significant technological innovations. Despite temporary setbacks during the COVID-19 pandemic, recovery has been swift with increased biopsy rates and renewed focus on early detection. Dominance of skin biopsy in diagnostics and hospital outpatient departments in service provision underscores the demand for effective and accessible care. The 40–59 age group represents the most proactive demographic in dermatological consultations. With ongoing advancements and a growing emphasis on preventive healthcare, the market is expected to sustain consistent growth through 2030.